TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28322776
Drug: 250 mL/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL/h of normal saline
Study: 28322776
Drug: 125 mL/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mL/h of 5% dextrose in normal saline
Study: 28322776
Drug: 250 mL/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL/h of 2.5% dextrose in normal saline
Study: 28322776
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (250 mL/h of normal saline)
Study: 28322776
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (125 mL/h of 5% dextrose in normal saline)
Study: 28322776
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (250 mL/h of 2.5% dextrose in normal saline)
Study: 24174945
Drug: Septal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Septal injection of 40 U of BTA (Dysport(®), Ipsen Ltd)
Study: 24174945
Drug: Turbinal injection
Normalized name: Karbinal
DrugBank: Carbinoxamine (DB00748)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Turbinal injection of 40 U of BTA (Dysport(®), Ipsen Ltd)
Study: 21696934
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol (FSC) 250/50 μg twice-daily
Study: 19929596
Drug: Intracameral bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intracameral bevacizumab injection at a concentration of 1.25 mg/0.05 mL
Study: 19929596
Drug: Intracameral bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intracameral bevacizumab injection
Study: 15116815
Drug: Fast-track rehabilitation
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-track rehabilitation with continuous epidural analgesia, enforced oral nutrition, mobilisation, planned early discharge
Study: 8404935
Drug: Streptokinase initiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase initiated 12-49 hours after onset of symptoms, followed by heparin for at least 5 days and warfarin and dipyridamole for at least 3 months
Study: 8404935
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment without any of these drugs
Study: 3950112
Drug: 1% indomethacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% indomethacin cream
Study: 3950112
Drug: 1% meclofenamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% meclofenamate cream
Study: 30374890
Drug: Remifentanil 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 12 ng/ml (Group 5)
Study: 30374890
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (including Group 1: 0 ng/ml, Group 2: 2 ng/ml, Group 3: 4 ng/ml, Group 4: 8 ng/ml, Group 5: 12 ng/ml)
Study: 26762908
Drug: Newer-generation drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer-generation drug-eluting stents (DES)
Study: 26762908
Drug: Older-generation drug-eluting
Normalized name: black alder pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older-generation drug-eluting stents (DES)
Study: 26762908
Drug: Creatinine clearance
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatinine clearance (CrCl) <45 ml/min
Study: 26762908
Drug: Creatinine clearance
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatinine clearance (CrCl) 45 to 59 ml/min
Study: 26762908
Drug: Creatinine clearance
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatinine clearance (CrCl) ≥60 ml/min
Study: 24332588
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy on the study side
Study: 24332588
Drug: Sham ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ozone therapy on the control side
Study: 20339731
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing + thought mapping + cognitive-behavioral group therapy
Study: 15935383
Drug: Rifampin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (300 mg twice daily) and Azithromycin (500 mg every other day) for 6 months
Study: 1895045
Drug: Early intravenous
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intravenous metoprolol followed by oral treatment for 15 days
Study: 15219654
Drug: Antenatal betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antenatal betamethasone treatment (2 doses of 12 mg administered intramuscularly to the mother twelve hours apart)
Study: 15219654
Drug: No antenatal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antenatal betamethasone treatment
Study: 12234700
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and VP-16 administered concurrently with radiotherapy (CRT)
Study: 9664953
Drug: CsA (original
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA (original formulation of cyclosporine)
Study: 2803892
Drug: Ephedrine 12.5
Normalized name: ePHEDrine 12.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 12.5 mg i.v. and 37.5 mg i.m.
Study: 16584949
Drug: Hands-on therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hands-on therapy including heat, massage, and active exercises
Study: 7952800
Drug: Propafenone administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone administered as a slow release formulation at 2 x 225 mg
Study: 7952800
Drug: Propafenone administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone administered as a slow release formulation at 2 x 325 mg
Study: 7952800
Drug: Propafenone administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone administered as a slow release formulation at 2 x 425 mg
Study: 3306493
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g of elemental calcium per day
Study: 25637395
Drug: Reference glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference glucose solution
Study: 23734572
Drug: Rupatadine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine 20 mg daily for 4 weeks
Study: 20142447
Drug: Bivalirudin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin plus glycoprotein IIb/IIIa inhibitors
Study: 18982784
Drug: Continuous interscalene
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous interscalene block (CIB) - 7 mL/h infusion of bupivacaine 0.0625% plus 1 microg/mL of sufentanil
Study: 18982784
Drug: Intra-articular analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular analgesia (IA) - 25 mL of ropivacaine 0.2% plus 2 mg of morphine
Study: 1524746
Drug: Carbamide peroxide
Normalized name: Carbamide Peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamide peroxide bleaching gel applied for three 2-hour periods per day for 9 days
Study: 1524746
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (5 teeth from each bonding agent group stored in water at 37 degrees C)
Study: 3159546
Drug: Preparation A
Normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation A (Trigynon, triphasic OC with low doses of ethinylestradiol and levonorgestrel)
Study: 3159546
Drug: Preparation B
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation B (Marvelon, monophasic OC with low doses of ethinylestradiol and desogestrel)
Study: 3159546
Drug: Preparation C
Normalized name: other nasal preparation combinations in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation C (Ovidol, sequential OC with higher doses of ethinylestradiol and desogestrel)
Study: 27314959
Drug: peginterferon beta-1a
Normalized name: Peginterferon Beta-1A
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peginterferon beta-1a 125 mcg administered subcutaneously every 2 weeks
Study: 27314959
Drug: peginterferon beta-1a
Normalized name: Peginterferon Beta-1A
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peginterferon beta-1a 125 mcg administered subcutaneously every 4 weeks
Study: 22855915
Drug: Cow's milk
Normalized name: Cow's milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cow's milk (600 mL/d)
Study: 22855915
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein isolate (SPI) beverage (840 mL/d; 30.1 mg total isoflavones/d)
Study: 22855915
Drug: Whole soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole soy bean (WSB) beverage (840 mL/d; 91.4 mg total isoflavones/d)
Study: 21086651
Drug: Emoxipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emoxipine (10 mg/kg, intravenous, 10-day course)
Study: 12269263
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (anthracycline-containing regimens)
Study: 7490154
Drug: 60 mmol
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mmol potassium and 25 mmol (1000 mg) calcium
Study: 7490154
Drug: 60 mmol
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mmol potassium and 15 mmol (360 mg) magnesium
Study: 31858615
Drug: Exhaled volatile
Normalized name: coal tar pitch volatiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exhaled volatile organic compounds (VOCs) analysis for CRC detection
Study: 31858615
Drug: Exhaled volatile
Normalized name: coal tar pitch volatiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exhaled volatile organic compounds (VOCs) analysis for advanced adenomas (AAs) detection
Study: 30502019
Drug: Acetaminophen/hydrocodone 325/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen/hydrocodone 325/5 mg (AH, opioid group)
Study: 30502019
Drug: Acetaminophen/ibuprofen 500/400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen/ibuprofen 500/400 mg (AIBU, nonopioid group)
Study: 28482350
Drug: Transfer Capacitive
Normalized name: SET,TRANSFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer Capacitive Resistive Energy (TCARE) therapy
Study: 23583457
Drug: Multidisciplinary non‐pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary non‐pharmacological treatment (four sessions)
Study: 11302006
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g isolated soy protein (ISP) daily
Study: 9005609
Drug: double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: double dose of lomir for 2 weeks
Study: 6723348
Drug: Spiramycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiramycin (500 mg 3-times daily for 3 days)
Study: 6723348
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg 3-times daily for 5 days)
Study: 27310418
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Depression Only (CBT)
Study: 29983749
Drug: Knee unloading
Normalized name: Bos taurus knee joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knee unloading shoes (ASICS GEL-Melbourne OA)
Study: 21029824
Drug: Vernakalant (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vernakalant (3 mg/kg for 10 minutes, followed by 2 mg/kg 15 minutes later if needed)
Study: 15811480
Drug: Ezetimibe (EZE)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe (EZE) 10 mg/d + Simvastatin (SIMVA) 10, 20, 40, or 80 mg/d
Study: 7497867
Drug: Standard 75-g
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard 75-g oral glucose tolerance test
Study: 30658845
Drug: 2000mg acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000mg acetaminophen (propacetamol)
Study: 27142328
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine (Boostrix(®)) during pregnancy
Study: 25517809
Drug: Tuberculin skin
Normalized name: tuberculin skin test; unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuberculin skin test (TST) followed by isoniazid preventive therapy (IPT)
Study: 19846355
Drug: EAM800x10 (moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EAM800x10 (moxifloxacin 400 mg b.i.d. for 10 days)
Study: 19846355
Drug: EAM800x7 (moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EAM800x7 (moxifloxacin 400 mg b.i.d. for 7 days)
Study: 19846355
Drug: EAM800x5 (moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EAM800x5 (moxifloxacin 400 mg b.i.d. for 5 days)
Study: 19846355
Drug: EAM400x10 (moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EAM400x10 (moxifloxacin 400 mg o.i.d. for 10 days)
Study: 19846355
Drug: Second-line rifabutin-based
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second-line rifabutin-based therapy after EAM800x10 and EAM800x7
Study: 12426976
Drug: 1 g/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/125 mg twice daily
Study: 12426976
Drug: 500 mg/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/125 mg three times a day
Study: 8520759
Drug: Nebulized morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized morphine 2.5 mg
Study: 8520759
Drug: Nebulized morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized morphine 5.0 mg
Study: 1836894
Drug: Paroxetine 30
Normalized name: PARoxetine 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 30 mg (evening)
Study: 7042363
Drug: ASA 1500
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASA 1500 + diazepam 6 mg/day
Study: 9851956
Drug: Intravenous deuterated
Normalized name: Deuterated water
DrugBank: Deuterium oxide (DB19251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous deuterated verapamil
Study: 8209272
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (MIP protocol: mitomycin 6 mg/m2 day I, ifosfamide 1.5 g/m2 days 1 to 3, cisplatin 30 mg/m2 days I to 3, mesna 1,200 mg/m2 days 1 to 3) followed by surgery and additional chemotherapy for responders.
Study: 2606121
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of 0.3 to 0.5 mg ethinyloestradiol (EE) daily
Study: 2606121
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of 0.1 mg ethinyloestradiol (EE) daily
Study: 28437161
Drug: Trastuzumab 8
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab 8 mg/kg → 6 mg/kg once every 3 weeks plus capecitabine 1,250 mg/m2 twice a day (2 weeks on, 1 week off, every 3 weeks)
Study: 28437161
Drug: Pertuzumab 840
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab 840 mg → 420 mg once every 3 weeks plus trastuzumab at the same dose and schedule as arm A plus capecitabine 1,000 mg/m2 on the same schedule as arm A
Study: 23022704
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg in 100 ml of isotonic saline, intravenously
Study: 23022704
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 ml of isotonic saline)
Study: 3166107
Drug: Diethylcarbamazine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylcarbamazine (300 mg) taken orally once a week
Study: 23993259
Drug: Celebrex 200
Normalized name: Celebrex 200mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celebrex 200 mg daily
Study: 18271901
Drug: Serum lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum lithium levels of 0.6-0.75 mmol/L
Study: 18271901
Drug: Serum lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum lithium levels >0.75 mmol/L
Study: 18271901
Drug: Abrupt reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrupt reduction of serum lithium levels >0.2 mmol/L
Study: 18271901
Drug: Serum lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum lithium level of 0.4 mmol/L
Study: 14624369
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor (PI) plus nevirapine
Study: 14624369
Drug: 3 nucleoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 nucleoside reverse‐transcriptase inhibitors (NRTIs) plus nevirapine
Study: 9097716
Drug: Scanning electron
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scanning electron microscopy with energy dispersive x‐ray analyses (microprobe‐SEM/EDXA) and atomic absorption spectroscopy (AAS)
Study: 27512098
Drug: Tui Na
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tui Na therapy
Study: 27512098
Drug: Placebo Tui
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tui Na therapy
Study: 24955104
Drug: Diaoshi Jifa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaoshi Jifa treatment
Study: 17251982
Drug: Bosentan 125
Normalized name: bosentan 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 125 mg b.i.d. for 6.5 days with rifampin 600 mg once a day
Study: 17251982
Drug: Bosentan 125
Normalized name: bosentan 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 125 mg b.i.d. for 6.5 days
Study: 11967516
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg capsule per day for 6 months)
Study: 9390958
Drug: CHO (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (1 g/kg)
Study: 23549037
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with cisplatin
Study: 23549037
Drug: Treatment without
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment without cisplatin
Study: 16298751
Drug: Daily fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily fruit (blueberries) consumption (250 g) for three weeks
Study: 16298751
Drug: Acute fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute fruit ingestion (250 g)
Study: 3109146
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g Mezlocillin administered at the time of narcosis for 20 min followed by 0.5 g Metronidazol for 10 min, given in 8-hour intervals for three days post-surgery.
Study: 3109146
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (Mezlocillin and Metronidazol) administered 30 min preoperatively and continued for three days postoperatively.
Study: 3109146
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no prophylactic antibiotic treatment).
Study: 30545653
Drug: Closed incisional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed incisional negative pressure wound therapy (ciNPWT)
Study: 26507336
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (Inofolic® plus): myo-inositol 4000 mg, folic acid 400 mcg, melatonin 3 mg
Study: 26507336
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (Inofolic®): myo-inositol 4000 mg, folic acid 400 mcg
Study: 26507336
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: only folic acid 400 mcg
Study: 14716729
Drug: Active prevention
Normalized name: CETYLPYRIDINIUM CHLORIDE 15 mg in 20 mL DENTAL RINSE [Colgate Total Active Prevention Spearmint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active prevention agents or placebo
Study: 9683207
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy (stavudine and nelfinavir)
Study: 9683207
Drug: Prolonged induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged induction therapy (saquinavir and nelfinavir)
Study: 9683207
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy (stavudine, lamivudine, saquinavir, and nelfinavir)
Study: 7830804
Drug: Methotrexate 25
Normalized name: methotrexate 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 25 mg i.m. once a week for 12 weeks, followed by tapering oral dose
Study: 3146726
Drug: High-dose cyclosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclosporin (16 mg/kg per day)
Study: 3146726
Drug: Low-dose cyclosporin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporin (9 mg/kg per day) with azathioprine (1 mg/kg per day)
Study: 3146726
Drug: High-dose cyclosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclosporin followed by conversion to azathioprine
Study: 29265187
Drug: Drinking apple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinking apple juice (0 ml, 50 ml, 100 ml, 200 ml, 300 ml, 400 ml)
Study: 26840338
Drug: Flexible dosing
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible dosing intervals (24±3 hours)
Study: 26840338
Drug: Fixed dosing
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dosing intervals (24 hours)